SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Norjavaara Ensio 1954)
 

Sökning: WFRF:(Norjavaara Ensio 1954) > Inhibition of estro...

Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial

Hero, M. (författare)
Norjavaara, Ensio, 1954 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för kvinnors och barns hälsa, Avdelningen för pediatrik,Institute for the Health of Women and Children, Dept of Paediatrics
Dunkel, L. (författare)
 (creator_code:org_t)
2005
2005
Engelska.
Ingår i: J Clin Endocrinol Metab. ; 90:12, s. 6396-402
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • CONTEXT: In males as well as in females, estrogen is an essential regulator of bone maturation, growth plate fusion, and cessation of longitudinal growth. Therefore, an increase in predicted adult height (PAH) may be achieved in short boys by blocking estrogen biosynthesis. OBJECTIVE: We tested the hypothesis that a decrease in the rate of bone maturation and an increase in PAH can be achieved in boys with idiopathic short stature (ISS) by the method of blocking estrogen biosynthesis with an aromatase inhibitor. Secondarily, we investigated the effects of aromatase inhibition on bone mineralization. DESIGN: This was a prospective, double-blind, randomized, placebo (Pl)-controlled clinical study. SETTING: The study was performed at a university hospital out-patient clinic. PATIENTS: Thirty-one boys, aged 9.0-14.5 yr, with ISS were studied. INTERVENTION: The boys were treated with the aromatase inhibitor letrozole (Lz; 2.5 mg/d) or Pl for 2 yr. MAIN OUTCOME MEASURE: The main outcome measure was the change in PAH after 24 months of treatment. RESULTS: PAH increased by 5.9 cm (P < 0.0001), and height SD score for bone age increased by 0.7 SD score (P < 0.0001) in the Lz-treated boys, whereas no changes occurred in the respective measures in Pl-treated boys. Areal bone mineral density of the lumbar spine and femoral neck, assessed by dual-energy x-ray absorptiometry, increased in a similar fashion in both groups during the treatment, whereas bone mineral apparent density increased only in those taking Lz (median increase, 4.3%; P = 0.009). CONCLUSIONS: Treatment with the aromatase inhibitor Lz delays bone maturation and improves PAH in boys with ISS. No adverse effects on bone mineralization were evident after 2 yr of treatment.

Nyckelord

Adolescent
Aromatase Inhibitors/*therapeutic use
Body Height/*drug effects
Bone Density/drug effects
Child
Densitometry
X-Ray
Double-Blind Method
Estrogen Antagonists/*therapeutic use
Femur Neck/metabolism/radiography
Growth/drug effects
Growth Disorders/*drug therapy/metabolism/physiopathology/radiography
Hormones/blood
Humans
Lumbar Vertebrae/metabolism/radiography
Male
Nitriles/*therapeutic use
Prognosis
Puberty
Research Support
Non-U.S. Gov't
Triazoles/*therapeutic use

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Hero, M.
Norjavaara, Ensi ...
Dunkel, L.
Artiklar i publikationen
Av lärosätet
Göteborgs universitet

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy